A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Trial Profile

A Long Term Study of YM060 in Female Patients With Diarrhea-predominant Irritable Bowel Syndrome

Completed
Phase of Trial: Phase III

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Ramosetron (Primary)
  • Indications Irritable bowel syndrome
  • Focus Registrational; Therapeutic Use
  • Sponsors Astellas Pharma
  • Most Recent Events

    • 26 May 2015 Astellas received approval in Japan for the treatment of diarrhoea-predominant irritable bowel syndrome in female patients from the Ministry of Health, Labour and Welfare, according to a company media release.
    • 15 Oct 2014 Status changed from active, no longer recruiting to completed according to ClinicalTrials.gov record.
    • 15 Apr 2014 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top